Cangrelor inhibits platelet activation in patients undergoing PCI
Jim Casey
This article has no abstract so we have provided the first paragraph of the full text.
Complications during percutaneous cardiac intervention (PCI) can be caused by platelet-initiated acute thrombosis and coronary embolization. The P2Y12-receptor antagonist cangrelor has been found to inhibit platelet activation. In a two-part study involving a total of 399 patients undergoing PCI, Greenbaum et al. assessed the safety and pharmacodynamics of cangrelor and compared this drug first with placebo and then with abciximab.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Nucleotides and cd39: Principal modulatory players in hemostasis and thrombosisNature Medicine News and Views (01 Sep 1999)
Humanizing mouse thrombiNature Biotechnology News and Views (01 Jan 2008)
Thrombi?beware of red cells bearing giftsNature Biotechnology News and Views (01 Aug 2003)
